Key Takeaways:
- Amoéba receives federal authorization from the U.S. Environmental Protection Agency (EPA) for AXPERA NOA and AXPERA GREEN
- Products target major fungal pathogens affecting high-value crops and turfgrass
- U.S. commercialization planned for 2026, pending California state review
- Authorization strengthens Amoéba’s partnership with Koppert for global distribution
- Field trials underway with the University of Florida ahead of full market rollout
Amoéba Gains Federal Authorization for AXPERA Products
Amoéba (FR0011051598 – ALMIB), a French greentech company specializing in microbiological crop protection, announced that it has received authorization from the U.S. Environmental Protection Agency (EPA) to commercialize its biocontrol products AXPERA NOA and AXPERA GREEN in the United States.
This authorization follows the EPA’s 2022 approval of Amoéba’s active biocontrol substance and marks a major step for the company’s entry into one of the world’s largest agricultural markets. The federal approval applies across all U.S. states except California, where a separate review process is ongoing with the Department of Pesticide Regulation.
AXPERA NOA and AXPERA GREEN are designed for high-value specialty crops such as vineyards, tomatoes, leafy vegetables, legumes, and berries, as well as turfgrass and ornamental plants. Both products have demonstrated efficacy against key fungal diseases including downy mildew, powdery mildew, rust, and fusarium.
Expanding Amoéba’s Biocontrol Footprint in the U.S.
Amoéba plans to begin commercial activities in 2026, initially targeting vegetable and vineyard growers. Production for the U.S. market will be carried out at Amoéba’s facility in Chassieu, France, and with selected Contract Development and Manufacturing Organization (CDMO) partners.
To support market introduction, the company will participate in major U.S. agricultural trade events alongside its distribution partners. Field trials are currently underway at several University of Florida research centers, including:
- Gulf Coast Research and Education Center (squash powdery mildew, cucumber downy mildew)
- Everglades Research and Education Center (lettuce downy mildew)
- Mid-Florida Research and Education Center (gerbera powdery mildew)
Amoéba Strengthens Partnership with Koppert
The EPA authorization reinforces Amoéba’s collaboration with Koppert, which holds exclusive distribution rights for AXPERA products in vineyards and open-field vegetable crops across the United States and 18 European countries. The five-year agreement with Koppert aims to accelerate the market rollout of the AXPERA range and expand its global reach.
“Obtaining this U.S. authorization, only months after our emergency approval in France and European-level recognition, confirms the strength of our engagement with regulatory agencies,” said Jean-Baptiste Eberst, Director of Regulatory Affairs at Amoéba.
Global Strategy and Next Steps for Amoéba
Amoéba continues to pursue additional regulatory authorizations in nine European countries, where outcomes are expected by early 2026. The company has already received final European Commission approval for its active substance and several temporary authorizations to support growers in the short term.
“With this milestone achieved on one of the world’s largest agricultural markets, we are now well positioned to meet grower needs with strong distribution partners,” said Jean-François Doucet, CEO of Amoéba, and Jean-Marc Petat, incoming CEO of Green 4 Agro.
Amoéba Looking Ahead
The U.S. EPA approval represents a key milestone in Amoéba’s international expansion strategy, supporting the company’s mission to provide effective, sustainable alternatives for crop protection. With partnerships, regulatory progress, and field validation in place, Amoéba continues to advance its biocontrol solutions for farmers worldwide.
